6th Annual MarketsandMarkets Net-Gen Immuno-Oncology Conference

WHAT TO EXPECT

Updates in development of ADC’s and Bispecific Ab’s
Immune Checkpoint Inhibitors and Combinations
Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
Biomarkers and Personalized Medicine in IO
CAR-T Cell therapy, TCR Based-Cell Therapy
Tumor microenvironment and Oncolytic Viruses

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

Monoclonal and Bispecific Antibodies
Cell Therapy
Immune Checkpoint Inhibitors

Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
Find out new case studies of immune-oncology projects in development
Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
Explore the latest platforms and technologies on the market for development
Discuss the best tool for your research in immune-oncology
Share your work and achievements with your industry peers in the Poster Session

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening remarks from the Chairman	08:55 - 09:00
New Antibody Formats & Cellular Therapy
Keynote: Immuno-oncology Continues to Transform Oncology Therapeutics Roy Baynes, Executive Vice President, Chief Medical Officer, Eikon Therapeutics	09:00 - 09:30
Solution Provider Presentation	09:30 - 10:00
Evaluating Efficacy of Novel Antibody and Cell-Based Therapeutics with Next-Generation Mouse Models Jenna Frame, Senior Scientist, Scientific Communications, Biocytogen	10:00 - 10:30
Morning Refreshments and Poster Presentations \| One-to-One Networking Meetings	10:30 - 11:15
Challenges and Opportunities for Immuno-oncology (IO) and Antibody Drug Conjugates (ADC) Therapeutics To Treat Cancers Rakesh Dixit, CEO, Bionavigen	11:15 - 11:45
Adoptive Cellular Therapy	11:45 - 12:15
Targeting cancer with ADC’s-Case study	12:15 - 12:45
Development of bispecific antibodies for cancer therapy	12:45 - 13:15
Lunch and Poster Presentations \| One-to-One Networking Meetings	13:15 - 14:15
Challenges in the nonclinical development of mAb-based cancer immunotherapy	14:15 - 14:45
Search for “right” molecule and “right” dose: Case Studies from immuno-oncology portfolio Ayse Meric Ovacik, Senior Principal Scientist, Genentech	14:45 - 15:15
Solution Provider Presentation	15:15 - 15:45
Afternoon Refreshments and Poster Presentations \| One-to-One Networking Meetings	15:45 - 16:30
Preclinical safety/toxicity evaluation of next generation CAR-T/TCR-T therapies Yixiang Xu, Senior Scientist, Bristol Meyers Squibb	16:30 - 17:00
Evaluating clinical and pharmacodynamic data of CLL patients treated with ibrutinib and an ADCC- enhanced anti-BAFF-R antibody (VAY736) Nadia Hassounah, Principal Scientist, Novartis	17:00 - 17:30
Choosing IO in multiple myeloma-Case Study	17:30 - 18:00
Closing remarks from the Chairman	18:00 - 18:00
End of Day 1 followed by Drinks Reception and Networking	18:00 - 18:00

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening remarks from the Chairman	08:55 - 09:00
New Immune Checkpoints, Biomarker and Tumour Microenvironment
Keynote:	09:00 - 09:30
Solution Provider Presentation	09:30 - 10:00
Role of Tumour Micro-Enviroment in Oncolytic Viral Therapy	10:00 - 10:30
Morning Refreshments and Poster Presentations \| One-to-One Networking Meetings	10:30 - 11:15
Solution Provider Presentation	11:15 - 11:45
New IO Combination therapies and Biomarkers	11:45 - 12:15
Next-generation checkpoints beyond PD-1 and CTLA-4	12:15 - 12:45
Cancer Vaccines and new developments	12:45 - 13:15
Lunch and Poster Presentations \| One-to-One Networking Meetings	13:15 - 14:15
Combining oncolytic viruses with immune checkpoint inhibitors	14:15 - 14:45
Solution Provider Presentation	14:45 - 15:15
Immunomodulation in IO	15:15 - 15:45
Closing remarks from the Chairman	15:45 - 15:45
End of Conference	15:45 - 15:45